Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia: A Managed Care Perspective

June 28, 2014
Junqing Liu, PhD, MSW

Supplements and Featured Publications, Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia, Volume 20, Issue 8 Suppl

Schizophrenia is a serious mental disorder associated with high morbidity and mortality, reduced life expectancy, and increased economic burden. Antipsychotic agents used for the management of schizophrenia are often associated with undesirable adverse effects, such as weight gain and metabolic abnormalities, contributing to elevated risk of cardiovascular disease, diabetes, and mortality. Contributors to the growing economic burden of schizophrenia include direct (eg, medical care and hospitalization) and indirect costs (eg, lost productivity and mortality). Strategies to reduce these expenditures include the use of generic medications, improving treatment adherence, avoidance of switching antipsychotic therapies, reducing disease relapses, and appropriate management of cardiometabolic disease. Arguably, while pharmacy benefit and managed care strategies (eg, prior authorization, prescription caps, copayments and patient cost-sharing strategies, tiered formulary pricing, and gap coverage) are designed and implemented to reduce healthcare costs, they may have the unintended result of creating barriers to treatment access and thereby contribute to further adverse patient outcomes. Managed care professionals should be cognizant of the drivers of cost and the need for cardiometabolic monitoring to individualize care for patients with schizophrenia. Further, comprehensive disease management plans should be developed that include the monitoring of disease progression and treatment adherence, while factoring in medication and healthcare administration costs.

Am J Manag Care. 2014;20:S174-S183The Burden of Disease in Schizophrenia

Despite the ongoing medical research into schizophrenia and the increasing amount of literature that is published every decade, the mental disorder continues to be incompletely understood. The annual incidence of schizophrenia ranges from 8 to 40 cases per 100,000 individuals, or 1 in 10,000 adults, with a relatively similar rate across all continents. In urban areas, the documented incidence of the mental disorder appears to be higher than in non-urban areas, with an overall lifetime risk of developing schizophrenia of approximately 0.7%.1,2 Although the cardinal features of positive (ie, impaired reality) and negative (ie, loss of range of affect, impulse, desire, volition, and striving) symptoms are central to schizophrenia, it has become further recognized that the psychotic phase of schizophrenia is preceded by a premorbid phase (ie, cognitive, motor, or social deficits) and a prodromal phase (ie, attenuated positive symptoms and/or functional decline).3 After the psychotic phase of excessive (ie, florid) positive symptoms, the patient enters a stable phase in which negative symptoms occur, with continuing cognitive, social, and functional decline. Following each psychotic episode, there are variable degrees of recovery to the patient’s baseline state of well-being. Consequently, disease control in the early stage of treatment is essential.3 In addition, schizophrenia is linked to at least a 1.9-fold increased rate of mortality, relative to healthy individuals, which is not entirely explained by disease-specific factors, such as an expected increased rate of suicide.4 One study published in 2008 demonstrated that when comparing their survival with the general population, patients with schizophrenia or schizoaffective disorder 30 years after initial diagnosis had a significantly higher mortality rate. Median survival following diagnosis was 35.9 years for people with schizophrenia and 39.3 years for patients with schizoaffective disorder. The leading causes of death among those patients were cardiovascular disease (CVD) (29%), neoplastic disease (19%), and pulmonary disease (17%).5

CVD is very prevalent among patients with schizophrenia. Compared with non-schizophrenia controls in a population-based study, patients with schizophrenia demonstrated higher rates of CVD (27% vs 17%, odds ratio [OR] 1.76; 95% CI 1.72-1.81)and diabetes (males aged 30 to 39 years, adjusted OR 1.57; 95% CI 1.3-1.91; females age 30 to 39 years, adjusted OR 1.72; 95% CI 1.44-2.04), and were more likely to be of older age and lower socioeconomic status.6 The increased risk of CVD associated with schizophrenia is further linked to a reduction in average life expectancy, relative to non-schizophrenic patients, of approximately 20% from 76 years (72 years in men, 80 years in women) to 61 years (57 years in men, 65 years in women). Two-thirds of patients with schizophrenia versus only half of patients without schizophrenia will eventually die of coronary heart disease (CHD).7 An examination of the predicted risk of CHD from the large-scale Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, compared with National Health and Nutrition Examination Survey III data, demonstrated a higher 10-year CHD risk in males (9.4% vs 7%; P = .0001) and females (6.3% vs 4.2%; P = .0001), higher smoking rates (68% vs 35%; P <.001), rates of diabetes (13% vs 3%; P <.001), and hypertension (27% vs 17%; P <.001), and lower high-density lipoprotein (HDL) cholesterol levels (43.7 vs 49.3 mg/dL; P <.001).8,9

Evidence has linked weight gain to the observed impaired glucose tolerance, higher rates of diabetes and hypertension, and increased mortality.10 One study from 2001 estimated that a mean weight gain of 2.5 kg per person would result in 366 additional diabetics and 1833 hypertensive patients per 100,000 people over 10 years, and similarly, a weight gain of 12.5 kg per person would result in an additional 2505 diabetic and 9169 hypertensive patients per 100,000 people. Further, the study linked a 2.5-kg and 12.5-kg weight gain per person to an additional 30 and 751 deaths per 100,000 people over 10 years, respectively.10 It is well documented that many of the antipsychotic medications typically used to treat schizophrenia are associated with the adverse effect of weight gain.11-13 To put the impact of medication-induced weight gain into perspective, Fontaine et al found that while clozapine would prevent 492 potential suicide deaths per 100,000 patients with schizophrenia, the weight gain associated with the use of clozapine would also result in 416 additional deaths over the same time period.10 Despite the clear link between these medications and weight gain, hypertension, and diabetes, it should be noted that patients with schizophrenia have also been reported to have impaired glucose tolerance prior to treatment with antipsychotic medications, suggesting a potential genetic linkage or susceptibility.14,15 All of these factors together highlight the significant burden of disease that is associated with the nonpsychiatric consequences of schizophrenia.

The Cost of Schizophrenia Treatment

Schizophrenia is a complex psychiatric disease that is very challenging to manage appropriately, and treatments are often associated with a high risk of nonpsychiatric morbidity and mortality, including CVD and diabetes. To achieve the delicate balance between efficacy and safety, it is important to examine the cost factors associated with the disease.

The direct and indirect costs associated with schizophrenia are summarized in Table 1.16-18 Direct medical costs include the expenses associated with treatment, such as psychotherapy, medication, and hospitalization, and the cost of managing complications, such as CVD and diabetes. Direct nonmedical costs include society’s cost of managing patients with schizophrenia in the community. CVD is the leading cause of death in the United States and accounts for 17% of all healthcare expenditures in the country. Between 2010 and 2030, the total direct cost (in 2008 dollars) resulting from CVD is projected to triple, from $273 billion to $818 billion. During that time, the indirect cost of CVD is also estimated to increase by 61%, from $172 billion to $276 billion.19 The estimated cost of diabetes in the United States was $245 billion in 2012, including $176 billion resulting from direct medical costs and $69 billion from indirect costs, a 47% increase from 2007.20 The overall economic burden of schizophrenia in 2002 was estimated to be $62.7 billion, with $22.7 billion in direct healthcare costs, $7.6 billion in direct non-healthcare costs, and $32.4 billion in indirect costs.16

Indirect costs associated with schizophrenia include the loss of productivity and the loss of life. While lost productivity has been shown to have the highest overall impact on the cost of schizophrenia, the direct healthcare expenditures associated with drug therapy, hospitalization, physician/psychiatric treatment, and long-term/ day care are also major drivers of the economic burden tied to schizophrenia.16-18 Relapse of psychotic symptoms and hospital admissions and readmissions are also important, potentially preventable drivers of cost in schizophrenia. According to a study published in 2013, patients with a relapse within the past 6 months increased the cost of care 4-fold relative to patients without a relapse.21 Adherence to antipsychotic medication therapy is a critical component of preventing relapse in patients with schizophrenia, because monthly relapse occurs in approximately 3.5% of patients who are maintained on neuroleptics versus 11% for patients who have discontinued their antipsychotic medication.22 Treatment nonadherence is estimated to occur in 7.6% of patients per month in the community setting, and approximately 40% of hospital readmissions for patients with schizophrenia are attributed to nonadherence, with 60% owing to the loss of neuroleptic efficacy.22 A study on factors associated with high schizophrenia-related costs published in 2013 demonstrated that patients with poor perceived health status were more likely to be in the high-cost treatment group, whereas patients who were older or who had a spouse were less likely to be in that high-cost group.23 Further, in comparison with older patients, younger patients, African Americans, patients with private insurance, or patients in the northeastern United States had higher relative schizophrenia-related direct medical costs, providing intriguing insight into potential drivers of cost for this complicated disease.23

In addition to the cost of medications, appropriate medication selection is an important cost driver because, depending on the patient, the choice of medication may affect treatment adherence, relapse rate, and hospital readmission.24 Goals of medication management are to achieve symptomatic remission, functional remission (eg, improved productivity), and an adequate level of subjective well-being, measured by a valid tool, such as the Subjective Well Being Under Neuroleptic Treatment Scale Short Form.24 Despite advances in psychosocial and pharmacologic treatment of schizophrenia, a study published in 2006 revealed that 90% of patients with the disease were unable to achieve the combined triple end point (symptomatic and functional remission with improved well-being) over at least 6 months of treatment.24 “Real-world” studies, which were intended to imitate practice more closely than a typical clinical trial, such as CATIE, the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1), and the European First-Episode Schizophrenia Trial (EUFEST), compared the less expensive first-generation antipsychotics (FGAs) with second-generation antipsychotics (SGAs) in an effort to establish a superior treatment.8,25-28 Unfortunately, the resulting data failed to demonstrate a clear preference for any 1 antipsychotic agent, and instead sparked controversy.29-31 FGAs have also been compared with SGAs in pharmacoeconomic studies that focused on lower acquisition costs.32,33 CATIE demonstrated that perphenazine, in the setting of similar overall efficacy and safety, was less costly than SGAs due to lower acquisition cost; however, this result has been questioned, because the patients who tolerated the FGA were selected for comparison with the SGA (ie, patients who were initially on an FGA were crossed over to treatment with an SGA).32 A similar conclusion, that the FGA was less expensive and outcomes were similar, was reached when olanzapine (ie, an SGA) was compared with haloperidol (ie, an FGA) in another study published in 2003 by Rosenheck et al.33 Pharmacoeconomic studies have also compared the SGAs to one another,34-40 and several of these studies demonstrated that increased cost containment may occur with improved adherence and/ or prevention of relapse/readmission.21,34-36 Other studies took a more global approach and evaluated the total cost of treating a patient, including adverse effects, such as the development of weight gain, diabetes, and CVD, and found that these factors contribute significantly to long-term patient outcomes and cost.37-40 Table 28,12,33,41-43 highlights several important differences between antipsychotic agents that affect short- and long-term costs, with the general findings indicating that SGAs are associated with reduced extrapyramidal symptoms but more weight gain than FGAs.

Accounting for the increased risk of developing diabetes and CVD, one of the biggest points of discussion surrounding the optimal management of schizophrenia is whether antipsychotic agents save lives or cost lives.44 Selecting the appropriate treatment for patients with schizophrenia is often a practice of balancing risk and benefit; however, it should be noted that patient mortality is generally reduced with pharmacologic treatment.44,45 A study published in 2009 demonstrated that long-term cumulative exposure to antipsychotic medication for 7 to 11 years was associated with a 19% reduction in mortality, and the risk of mortality varied by agents, as shown in the Figure.45 Another study from 2007 evaluated cardiovascular- and cancer-related mortality in patients receiving antipsychotic medications and found that while the risk of developing non-respiratory cancer was not increased, patients on the highest prescribed doses of antipsychotics had a 1.4- to 4-fold increase in CHD mortality and twice the risk of death from stroke.46

Lastly, there are differences in tolerability and efficacy between the various antipsychotics that may lead to frequent medication switches, which is another important cost driver. These therapeutic switches are associated with increased resource utilization, and a study published in 2009 identified a 25% increase in annual total healthcare costs per patient who had switched medications.47,48 Furthermore, rates of discontinuation can be very high in practice; for instance, 74% by 18 months in the CATIE trial.8

Managed Care Implications

Despite studies like CATIE and CUtLASS-1, which supported FGAs as a means to provide cost-effective care, there has been a dramatic rise in SGA prescriptions,8,25,49 resulting in concerns of increased medication costs and negative consequences to cardiovascular health.49 Health plans, pharmacy benefit managers, and managed care organizations have developed strategies to control these costs, including strategies such as step therapy, prior authorization, tiered formulary pricing, and increased education or counter-detailing, where physicians were educated on the benefits of generic medications.50 However, notably, the counter-detailing strategy has been found to be ineffective for reducing SGA prescriptions in a Veterans Health Administration setting, with prescribers citing improved efficacy (48.9%), reduced side effects (29.1%), and increased sleep or sedation (34.5%) as the predominant reasons for choosing an SGA.51 Another study by Soumerai et al evaluated the implementation of a 3-prescription monthly Medicaid cap on psychotropic medication for patients with schizophrenia, which resulted in an immediate 15% to 49% reduction in the number of prescriptions filled for antipsychotic drugs, antidepressants, lithium, anxiolytics, and hypnotics (P <.01).52 This reduction was associated with an increase of 1 to 2 visit(s) (43%-57%; P <.001) per patient per month to community mental health centers, and an increase of 1.2 to 1.4 episodes per patient per month for emergency mental health services and partial hospitalization, but not inpatient hospitalization. The use of medications and mental health services reverted to baseline levels when the Medicaid cap was rescinded, and over the remaining course of the 42-month pilot program, the mental healthcare costs per patient then exceeded the drug savings 17-fold. Medication costs decreased $5.14 ± 0.67 per patient per month, while the total cost increased $139 per patient per month due to increased utilization of other resources.52 To a similar degree, programs with prior authorizations, donut hole gaps, and copayments may inadvertently create barriers to medication access and reduce medication continuity, which may further lead to increased utilization of other resources, such as inpatient services.53-56

Evidence has shown the challenges of maintaining continuity in medication therapy when cost is applied to the patient. Unfortunately, recent legislative activity may not improve this situation, with proposed changes to Medicare Part D that will limit the patient’s choice of antipsychotic medications, despite the American Psychiatric Association’s stance that having a broader selection of antipsychotics to choose from is necessary due to the various unique drug effects and tolerability.57 Furthermore, lack of coverage once patients reach the donut hole, where medication costs are patient out-ofpocket (OOP) expenses, in accountable care organization models may lead to an increase in self-rationing of medications by the patients and consequent hospitalizations, because 56% of patients with schizophrenia are expected to hit the gap.55,58 In addition, mental health parity rules may actually have the opposite effect by limiting certain benefits, like residential coverage or copayment requirements, resulting in further patient OOP expenses.59

Merging Clinical Data and Treatment Pathways to Improve Patient Care

Based on compiled prescription data, patients with schizophrenia are primarily treated by psychiatrists and general practitioners, who prescribe 49% and 37% of antipsychotic prescriptions, respectively.60 However, published studies have revealed that guideline compliance is poor in outpatients.61,62 There are currently 5 major guidelines/ algorithms developed for the treatment of schizophrenia in the United States: the American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia63; the Schizophrenia Patient Outcomes Research Team treatment recommendations64; the Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia65; the International Psychopharmacology Algorithm Project66; and the Expert Consensus Guidelines.67 There are also European guidelines, including the recently released National Institute for Health and Clinical Excellence schizophrenia guideline from the United Kingdom, and several others.68-70 It is important to note that each guideline may differ slightly in scope, focus, and goals as a result of using different criteria for its establishment. Although CATIE and CUtLASS-1 supported the first-line use of FGAs, it should be recognized that these studies selected patients who tolerated FGAs to compare with the use of SGAs, and in reality, choosing an appropriate antipsychotic may rely more on patient-specific factors, as outlined earlier in this supplement.8,13,25,29,71,72 Unfortunately, current cost-containment strategies may restrict access to an optimal medication therapy based on patient-specific factors, which would actually result in further use of costly healthcare services that might have otherwise been avoided, such as intensive outpatient follow-up or (re)hospitalization.52 As mentioned in an article published in 2010, although it is reasonable to attempt the first-line use of an FGA from a cost-effectiveness perspective, “We [practitioners] are forced to acknowledge that [the] choice of antipsychotic is (as it was when we had only FGAs) guided largely by side effects [experienced by the patient].”71,72

Perhaps the most important potential adverse effects to manage when using FGAs or SGAs in patients with schizophrenia are metabolic abnormalities and/or CVD. Although extrapyramidal symptoms and tardive dyskinesia can increase mortality, CVD continues to be the greatest contributor to death in patients with schizophrenia.5,7,43 Concordance with guidelines and treatment recommendations to monitor metabolic risk are low, with only 60% to 70% of patients with schizophrenia having their blood pressure and triglycerides monitored, 41% to 48% of patients having their cholesterol, glucose, and weight monitored, and less than 25% of patients having their lipids and glycated hemoglobin monitored.73

Consequently, the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) 2014 contains 4 new performance measures to increase accountability in healthcare for the benefit of patients with schizophrenia.74 HEDIS measures were implemented to establish accountability in healthcare and to aid physicians in quality improvement by measuring quality at the health plan level for purchasers of healthcare.74 As mentioned, prior to HEDIS, concordance with guideline recommendations for diabetes and CVD monitoring in schizophrenia was low.71 The new measures for schizophrenia (Table 373-75) were first released in 2013 and are also contained in the 2014 update.74 The HEDIS measures relating to schizophrenia are expected to improve monitoring, and consequently treatment, of diabetes and CVD in these patients, and also focus on improving treatment adherence.74 As noted previously, CVD is the leading cause of death in schizophrenia, so improved identification and management of CVD and diabetes is expected to reduce mortality.6,7 In addition, antipsychotic treatment for schizophrenia has been linked to reduced mortality and resource utilization, so efforts to improve compliance should improve those outcomes.45,52 Identifying patients at risk for CVD, diabetes, and treatment nonadherence is a paramount first step in improving patient mortality outcomes in schizophrenia.

Once a patient is identified, an individualized treatment plan is required. Due to the pitfalls associated with switching medications and the nuances in efficacy, adverse effects, tolerability, and patient adherence among the various agents, it is likely that the metabolic and cardiovascular consequences associated with SGA therapies cannot be alleviated by simply discontinuing treatment.22,47,48,71 Fortunately, patients with schizophrenia can still be successfully managed with SGAs, as long as they are monitored for the metabolic and cardiovascular adverse effects of such treatment. A position statement from the European Psychiatric Association, supported by the European Association for the Study of Diabetes and the European Society of Cardiology, provides monitoring and treatment recommendations.75 These guidelines provide recommendations for cardiovascular risk assessment and management by requiring the following for all patients with severe mental illness first encountered by a clinician and all patients beginning or switching medication: A thorough history; examination of body weight, blood pressure, waist circumference, and body mass index; laboratory assessment of fasting glucose and lipids, total cholesterol, low-density lipoprotein cholesterol, HDL cholesterol, and triglycerides; and counseling on smoking cessation, food choices, and physical activity. Then, based on the risk assessment findings, the guideline provides recommendations for treatment, type, and timing of follow-up monitoring.75

Medication adherence is also a critical component of care for patients with schizophrenia, and intensive counseling alone does not appear to improve outcomes.76 Mitigating or eliminating high costs to the patient and selecting an antipsychotic agent that is efficacious and well tolerated are the best strategies to improve treatment adherence. The use of long-acting injectable formulations is one such method that may achieve a higher rate of compliance to therapies for schizophrenia, and may reduce disease relapse and hospital (re)admission in those who are nonadherent to oral therapies (even though studies have failed to show improvement in unselected populations, because they included all patients rather than only those who were nonadherent to therapy).77-79

Conclusion

The challenges outlined in this article underscore the currently unmet need for managed care professionals to consider the whole picture when attempting to minimize the high costs associated with treating schizophrenia. While SGAs, the standard of care for schizophrenia, have certainly improved patient outcomes, disease relapse, and rates of hospital admissions, it is crucial to individualize the treatment of patients with the disease and to closely monitor the associated metabolic and cardiovascular consequences to prevent further poor clinical and economic outcomes downstream. The implementation of HEDIS and quality measures is expected to improve monitoring for adverse metabolic and CVD outcomes and improve medication adherence, resulting in improved overall care of patients with schizophrenia. Managed care professionals must translate the available evidence into comprehensive disease management plans that include stringent monitoring of disease progression and treatment adherence, and effectively balance the implementation of best clinical practices with cost-containment strategies.Author affiliation: National Committee for Quality Assurance, Washington, DC.

Funding source: This activity is supported by educational grants from Jazz Pharmaceuticals and Otsuka America Pharmaceutical, Inc.

Author disclosure: Dr Liu reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Authorship information: Concept and design; acquisition of data; drafting of the manuscript; and critical revision of the manuscript for important intellectual content.

Address correspondence to: E-mail: liu@ncqa.org.

  1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts”: what we know in 2008 part 1: overview. Schizophr Res. 2008;100(1-3):4-19.
  2. Häfner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry. 1997;42(2):139-151.
  3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1-3):1-23.
  4. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophr Bull. 1996;22(3):485-499.
  5. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98(1-3):287-294.
  6. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117(1): 75-82.
  7. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-1121.
  8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
  9. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of tenyear cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1): 45-53.
  10. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-288.
  11. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment — pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-179.
  12. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
  13. Javitt DC. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: exploring the treatment landscape. Am J Manag Care. 2014;20(8 suppl):S166-S173.
  14. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160(2):284-289.
  15. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007;24(5):481-485.
  16. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-1129.
  17. Cortesi PA, Mencacci C, Luigi F, et al. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry. 2013;13:98.
  18. McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull. 1991;17(3):375-388.
  19. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
  20. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
  21. Rajagopalan K, O’Day K, Meyer K, Pikalov A, Loebel A. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. J Med Econ. 2013;16(8):987-996.
  22. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429.
  23. Desai PR, Lawson KA, Barner JC, Rascati KL. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J Manag Care Pharm. 2013;19(6):468-477.
  24. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67(11):1690-1697.
  25. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
  26. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1). Schizophr Res. 2013;144(1-3):80-86.
  27. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
  28. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2-3):97-103.
  29. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649-659.
  30. Jayaram M, Rattehalli RD, Adams CE. Where does evidence from new trials for schizophrenia fit with the existing evidence: a case of the emperor’s new clothes? Schizophr Res Treatment. 2012;2012:625738.
  31. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs. 2012;26(6):491-508.
  32. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-2089.
  33. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290(20):2693- 2702.
  34. Rajagopalan K, Hassan M, O’Day K, Meyer K, Grossman F. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. J Med Econ. 2013;16(7):951-961.
  35. O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Longterm cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459-470.
  36. Achilla E, McCrone P. The cost effectiveness of long-acting/ extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11(2):95-106.
  37. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.
  38. Ward A, Quon P, Abouzaid S, et al. Cardiometabolic consequences of therapy for chronic schizophrenia using secondgeneration antipsychotic agents in a Medicaid population: clinical and economic evaluation. P T. 2013;38(2):109-115.
  39. Kasteng F, Eriksson J, Sennfält K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124(3):214-225.
  40. McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16(4):744-755.
  41. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet. 2009;373(9657):31-41.
  42. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
  43. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393-406.
  44. Mitchell AJ. Do antipsychotics cost lives or save lives? risks versus benefits from large epidemiological studies. J Clin Psychopharmacol. 2009;29(6):517-519.
  45. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
  46. Osborn DP, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry. 2007;64(2):242-249.
  47. McCombs J, Zolfaghari S, Ganapathy V. Impact of drug treatment history on comparative effectiveness research in schizophrenia. Value Health. 2011;14(5):679-686.
  48. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9:54.
  49. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010;121(1):4-10.
  50. Rosenheck RA, Sernyak MJ. Developing a policy for second-generation antipsychotic drugs. Health Aff (Millwood). 2009;28(5):w782-w793.
  51. Hermes ED, Sernyak M, Rosenheck R. Impact of a program encouraging the use of generic antipsychotics. Am J Manag Care. 2012;18(8):e307-e314.
  52. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655.
  53. Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT. Medication continuity among Medicaid beneficiaries with schizophrenia and bipolar disorder. Psychiatr Serv. 2013;64(9):878-885.
  54. Vogt WB, Joyce G, Xia J, et al. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Aff (Millwood). 2011;30(12):2346- 2354.
  55. Smith KJ, Baik SH, Reynolds CF 3rd, Rollman BL, Zhang Y. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care. 2013;19(2):e55-e63.
  56. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004;7(1):22-35.
  57. Carroll J. Medicare’s part D fiasco triggers anger from all sides. Manag Care. 2014; 23(4):39-40.
  58. Wehrwein P. Pharmacy benefit management in the new world of ACOs. Manag Care. 2014;23(4):34-38.
  59. Burns J. Not making sense of mental health parity rules. Manag Care. 2014;23(2):28-30.
  60. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9): 1167.
  61. Dickey B, Normand SL, Hermann RC, et al. Guideline recommendations for treatment of schizophrenia: the impact of managed care. Arch Gen Psychiatry. 2003;60(4):340-348.
  62. Stiles PG, Boothroyd RA, Dhont K, Beiler PF, Green AE. Adherence to practice guidelines, clinical outcomes, and costs among Medicaid enrollees with severe mental illnesses. Eval Health Prof. 2009;32(1):69-89.
  63. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1-56.
  64. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
  65. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751-1762.
  66. The International Psychopharmacology Algorithm Project. www.ipap.org. Accessed April 24, 2014.
  67. Treatment of schizophrenia 1999: the expert consensus guideline series. J Clin Psychiatry. 1999;60(11 suppl):3-80.
  68. National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence Clinical Guideline 178: psychosis and schizophrenia in adults: treatment and management. National Institute for Health and Care Excellence website. http://www.nice.org.uk/nicemedia/live/14382/66529/66529.pdf. Accessed April 17, 2014.
  69. Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2-44.
  70. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
  71. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry. 2010;55(3):117-125.
  72. Javitt DC. Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. Curr Treat Options Psychiatry. 2014;1:107-120.
  73. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and metaanalysis of screening practices. Psychol Med. 2012;42(1):125-147.
  74. National Committee for Quality Assurance. HEDIS 2014, Volume 2: Technical Specifications for Health Plans. Washington, DC: National Committee for Quality Assurance; 2013.
  75. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412-424.
  76. Patel A, McCrone P, Leese M, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries. Cost Eff Resour Alloc. 2013;11(1):12.
  77. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.
  78. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28(2):57-66.
  79. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso- Escalano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41-53.